Clinical trials: HIV -1 Infection
HIV-1 Infection
Efficacy, Safety, and Tolerability of Cenicriviroc (CVC) in Combination With Truvada or Sustiva Plus Truvada in HIV 1-infected, Antiretroviral Treatment-naïve, Adult Patients Infected With Only CCR5-tropic Virus
This is a randomized, double-blind, double-dummy, 48-week, comparative study. Approximately 150 HIV-infected, treatment-naïve patients with CCR5-tropic virus will be stratified by HIV-1 RNA: ≥100,000 copies/mL versus <100,000…
- Trial name
- NCT01338883
- Testing
- Cenicriviroc 100 mg, Cenicriviroc 200 mg + Truvada, Sustiva + Truvada
- Where
- 48 sites in United States, Puerto Rico
- Volunteers
- 143 people
- Sponsor
- Tobira Therapeutics, Inc.
HIV-1-infection
Immediate or Deferred Pre-exposure Prophylaxis for HIV Prevention: Safe Options for Pregnant and Lactating Women
An Open Label randomized control study. To explore the safety of Truvada when used as PrEP during pregnancy and lactation. Pregnant women considered at risk for HIV infection and willing to participate in this randomized control…
- Trial name
- PrEP (NCT03227731)
- Testing
- Truvada
- Where
- South Africa
- Volunteers
- 540 people, healthy volunteers welcome
- Sponsor
- University of KwaZulu
HIV Infections
Immunogenicity and Safety Trial of the HIV-1 Tat Vaccine
The study is a randomized, open label, phase II clinical trial directed at evaluating the immunogenicity (as a primary end-point) and the safety (as a secondary end-point), of the recombinant HIV-1 Tat vaccine in HIV-1 infected…
- Trial name
- ISS T-002 (NCT00751595)
- Testing
- Tat protein
- Where
- 11 sites in Italy
- Volunteers
- 168 people
- Sponsor
- Barbara Ensoli, MD
Hepatitis B, HIV Infection
Trial Comparing Two Strategies of Vaccination Against Hepatitis B in HIV-infected Patients Non Responding to Primary Immunization (B-BOOST)
HIV infected patients exposed to Hepatitis B virus are more susceptible to develop a chronic and severe liver disease, with a major risk of cirrhosis and liver cancer.
- Trial name
- B-BOOST (NCT00670839)
- Testing
- GenHevac-B
- Where
- France
- Volunteers
- 178 people
- Sponsor
- ANRS, Emerging Infectious Diseases
HIV Infections
An Expanded Access Open Label Protocol of Remune (HIV-1 Immunogen) in HIV-1-Infected Adults With CD4 Count 550 Cells /Ml and Greater.
To provide an alternative therapy to HIV-infected patients for whom there is no comparable or satisfactory alternative drug or therapy available.
- Trial name
- NCT00002173
- Testing
- HIV-1 Immunogen
- Where
- United States
- Sponsor
- The Immune Response Corporation
Sexually Transmitted Infections, HIV Infections
Sexually Transmitted Infections Among African American Women Who Have Sex With Women
The purpose of this study is to determine the rates of sexually transmitted infections (STI) among a group of African American women who have sex with women (AA WSW).
- Trial name
- WSW (NCT01043081)
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- University of Mississippi Medical Center
HIV-1-infection
Safety and Pharmacokinetics of the Combination Broadly Neutralizing Antibodies, 3BNC117-LS-J and 10-1074-LS-J, in Healthy American and African Adults
This is a Phase 1/2 study to evaluate the safety, tolerability, and pharmacokinetics of two broadly neutralizing monoclonal human antibodies (bNAbs), 3BNC117-LS-J, which targets the CD4 binding site on HIV-1 envelope protein, and…
- Trial name
- NCT04173819
- Testing
- 3BNC117-LS-J, 10-1074-LS-J, Combination 3BNC117-LS-J and 10-1074-LS-J
- Where
- 9 sites in United States, Kenya and 3 more
- Volunteers
- 225 people, healthy volunteers welcome
- Sponsor
- International AIDS Vaccine Initiative
HIV Infections
Evaluating the Safety and Drug Levels of an Antibody Against HIV in Healthy, HIV-Uninfected Adults
Antibodies are natural proteins that the body makes to fight infections. Antibodies can also be manufactured like a drug and infused or injected into the body to prevent or treat a disease.
- Trial name
- NCT02165267
- Testing
- VRC01
- Where
- 6 sites in United States
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV-1 Infection
The Effect of Probiotics in HIV-1 Infection
HIV progression is closely associated with chronic immune activation driven by leakage of bacterial products from a damaged gut, the investigators largest immunological organ.
- Trial name
- ProGut (NCT01439841)
- Testing
- Multi-strain probiotic
- Where
- 2 sites in Norway, Sweden
- Volunteers
- 32 people
- Sponsor
- Oslo University Hospital
Opioid-use Disorder, HIV-1-infection
Anti-retroviral Therapy, Medications for Opioid Use Disorder, Opioids and HIV Infection - Study 1
HIV infection, as well as exposure to opioids (including heroin), are associated with systemic immune activation including increased microbial translocation from the gut.
- Conditions
- Opioid-use Disorder, HIV-1-infection, Immune Activation, Inflammation
- Trial name
- AMOHI-1 (NCT04480554)
- Testing
- Methadone, Buprenorphine/naloxone, XR-Naltrexone
- Where
- 2 sites in United States, Vietnam
- Volunteers
- 78 people
- Sponsor
- University of Pennsylvania
Hiv
Early Administration of Romidepsin and 3BNC117 in Treatment-naïve HIV Patients Starting ART
To evaluate the effect of early viral reactivation by latency reversing agents (LRA) and/or administration of potent broadly neutralizing antibodies (bNAb) on the size of the latent HIV-1 reservoir in treatment naïve HIV-1…
- Trial name
- eCLEAR (NCT03041012)
- Testing
- Romidepsin, 3BNC117, Antiretrovirals
- Where
- 7 sites in Denmark, United Kingdom
- Volunteers
- 60 people
- Sponsor
- Aarhus University Hospital
Hepatitis C, Human Immunodeficiency Virus
Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2 and 3 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Adults
This study will evaluate the efficacy, safety, and tolerability of sofosbuvir (SOF; GS-7977) plus ribavirin (RBV) in adults with chronic genotypes 1, 2, and 3 HCV infection who are coinfected with HIV-1.
- Trial name
- NCT01667731
- Testing
- SOF, RBV
- Where
- 27 sites in United States, Puerto Rico
- Volunteers
- 224 people
- Sponsor
- Gilead Sciences
HIV Infections, Leukoencephalopathy, Progressive Multifocal
A Pilot Study of the Efficacy of Recombinant Alpha Interferon (IFN-A2b) and Zidovudine (AZT) in the Treatment of Progressive Multifocal Leukoencephalopathy (PML) Complicating HIV-1 Infection
To study the effectiveness of alpha interferon (IFN-A2b) and zidovudine (AZT) in treating progressive multifocal leukoencephalopathy (PML) as a complication of HIV-1 infection.
- Trial name
- NCT00002270
- Testing
- Interferon alfa-2b, Zidovudine
- Where
- United States
- Sponsor
- University of Miami
HIV-1-infection
Effectiveness, Safety, Adherence, and Health-related Quality of Life in HIV-1 Infected Adults Receiving Bictegravir/ Emtricitabine/Tenofovir Alafenamide (B/F/TAF)
The primary objective of this study is to evaluate HIV-1 RNA suppression, defined as HIV-1 RNA < 50 copies/mL, at 12 months after initiating or switching to bictegravir/ emtricitabine/tenofovir alafenamide (B/F/TAF).
- Trial name
- BIC-STaR (NCT04009057)
- Testing
- B/F/TAF
- Where
- 5 sites in Israel
- Volunteers
- 143 people
- Sponsor
- Gilead Sciences
HIV-1-infection
Gut Microbiota and Immune Recovery
To explore whether gut microbiota would impact CD4 T cells recovery in HIV-infected patients on antiretroviral therapy (ART). We prospectively enroll patients initiate ART and collect their fecal at followup for one year.
- Trial name
- NCT03478540
- Testing
- Anti-Retroviral Agents
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Shanghai Public Health Clinical Center
HIV Infections
A Study to Evaluate the Safety and Efficacy of Raltegravir (MK0518) in HIV-Infected Patients Failing Current Antiretroviral Therapies (0518-019)
This study will investigate the safety and efficacy of raltegravir as a therapy for Human Immunodeficiency Virus (HIV)-infected patients failing current therapy with 3-class antiviral resistance.
- Trial name
- NCT00293254
- Testing
- raltegravir potassium
- Volunteers
- 351 people
- Sponsor
- Merck Sharp & Dohme LLC
Hiv, Kidney Transplant
Impact of Sirolimus and Maraviroc on CCR5 Expression and the HIV-1 Reservoir in HIV-infected Kidney Transplant Recipients
The purpose of this proof of concept, pilot study is to determine whether the unique combination of the human immunodeficiency virus (HIV) co-receptor antagonist, Maraviroc, and the mammalian target of rapamycin (mTOR) inhibitor…
- Conditions
- Hiv, Kidney Transplant, HIV Reservoir, CCR5
- Trial name
- NCT02990312
- Testing
- Sirolimus + Maraviroc
- Where
- United States
- Sponsor
- University of Maryland, Baltimore
Hepatitis C, Chronic
Phase III Trial of BI 201335 (Faldaprevir) in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)-Human Immunodeficiency Virus (HIV) Coinfected Patients (STARTverso 4)
the aim of this trial is to evaluate the efficacy and the safety of BI 201335 given for 12 or 24 weeks in combination with PegIFN/RBV given for 24-48 weeks, according to re-randomisation of Early Treatment Success (ETS) patients…
- Trial name
- NCT01399619
- Testing
- PegIFN/RBV, BI201335, BI201335 24W
- Where
- 71 sites in United States, Brazil and 6 more
- Volunteers
- 310 people
- Sponsor
- Boehringer Ingelheim
Cytomegalovirus Infections, HIV Infections
Trial to Evaluate the Safety and Immunogenicity of a Modified Vaccinia Ankara (MVA)-Based Anti-Cytomegalovirus (CMV) Vaccine (Triplex®)
A5355 was a randomized, placebo-controlled study conducted at US sites to evaluate the safety and immunogenicity of two injections of the study drug Modified Vaccinia Ankara (MVA)-based anti-Cytomegalovirus (CMV) Vaccine…
- Conditions
- Cytomegalovirus Infections, HIV Infections, Vaccine
- Trial name
- NCT05099965
- Testing
- CMV-MVA Triplex
- Where
- 12 sites in United States
- Volunteers
- 94 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Infection, Human Immunodeficiency Virus I, HIV Infection
Observational Study Of A Protease Inhibitor (PI) Containing Regimen In Subjects With PI Mutations Selected During Prior Treatment With GW433908 (Fosamprenavir)
This study will assess the efficacy of subsequent protease inhibitor (PI)-containing therapy in subjects who have acquired HIV-1 protease mutations whilst receiving a GW433908 (fosamprenavir)-containing regimen.
- Trial name
- NCT00242840
- Testing
- No intervention; Observational study
- Where
- 7 sites in United States, Italy
- Volunteers
- 20 people
- Sponsor
- ViiV Healthcare
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.